Session » Rheumatoid Arthritis – Animal Models - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1452

18 F-FDG PET Imaging: An In Vivo quantitative Drug Screening Tool for Novel Antiinflammatory Therapies

9:00AM-11:00AM: Abstract Number: 1443

A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1440

Anti-TNF Vaccination Protects from Experimental Arthritis without Affecting Resistance to Mycobacterium Tuberculosis or Listeria Monocytogenes infection

9:00AM-11:00AM: Abstract Number: 1455

Collagen-Induced Arthritis and Uveitis in Mice Lacking TNF Receptors

9:00AM-11:00AM: Abstract Number: 1454

Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 1441

Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Knockout Attenuates Arthritis Progression and Systemic Inflammation in TNF-Tg Arthritis Mouse Models

9:00AM-11:00AM: Abstract Number: 1444

Differential Expression of Wnt Inhibitors before and after Joint Inflammation Onset in Rat Arthritis Could Partly Explain Paradoxical Effect of Sclerostin Inhibition

9:00AM-11:00AM: Abstract Number: 1457

Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1434

Effect of Systemic and Local Inflammation on the Insulin Resistance and Glucose/Lipid Metabolism in Rheumatoid Arthritis: Humans and CIA Mouse Model

9:00AM-11:00AM: Abstract Number: 1459

Enhanced Efficacy of Early Vs. Late IL-1β Antagonism in Murine Arthritis Mediated By Deficiency of the IL-1 Receptor Antagonist IL-1ra

9:00AM-11:00AM: Abstract Number: 1451

Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1463

Helminths Based Tuftsin-Phosphorylcholine Prevent Development of Mouse Collagen Induced Arthritis, While Maintaining Normal Gut Microbiota

9:00AM-11:00AM: Abstract Number: 1446

High Fat Diet Alleviates Antigen-Induced Arthritis Severity in Male Mice By Enhancing Both Treg and B10 Cells

9:00AM-11:00AM: Abstract Number: 1445

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Ameliorate Rheumatoid Arthritis Via Regulation of Macrophage Activation and Polarization

9:00AM-11:00AM: Abstract Number: 1456

Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1458

Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?

9:00AM-11:00AM: Abstract Number: 1435

KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1462

Magnesium Is a New Mediator Arthritis Severity and Joint Damage

9:00AM-11:00AM: Abstract Number: 1461

Modification of Proteins with Malondialdehyde-Acetaldehyde and Citrulline Elicit Antibody Responses in DBA/1J Mice

9:00AM-11:00AM: Abstract Number: 1437

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1450

Regulatory Mechanisms of Mesenchymal Stem Cell Transplantation on Systemic Osteoporosis in Collagen-Induced Arthritis Mice

9:00AM-11:00AM: Abstract Number: 1442

Suppression of Acute Arthritis By N-Methyl-3,4-Dichloropropionaniline (N-MeDCPA), a Reversible Orai Calcium Channel Inhibitor

9:00AM-11:00AM: Abstract Number: 1460

Suppression of Cholesterol Levels and Impairment in Cholesterol Efflux By HDL in K/BxN Mice Is Associated with a Specific Cytokine/Chemokine Profile

9:00AM-11:00AM: Abstract Number: 1436

TAS8274, a Highly Selective Janus Kinase 3 Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1449

The Efficiency of the Regulation of Ca2+ Entry through Calcium Release-Activated Calcium Channel in the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1439

The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants

9:00AM-11:00AM: Abstract Number: 1447

Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis

9:00AM-11:00AM: Abstract Number: 1448

Therapeutic Role of a Novel Histone Deacetylase 6 Inhibitor, CKD-M808, in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1438

Tofacitinib Restores Reverse Cholesterol Transport Inhibition Induced By Inflammation. Understanding the Lipid Paradox

9:00AM-11:00AM: Abstract Number: 1453

Treatment of BAFF Transgenic Mice with Anti-TNF: Monoclonals Are Associated with a Higher Risk of Lymphoma Than Etanercept

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].